A Phase 3 interventional study of Pramipexole in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 44 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-11-08.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.
Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 5th largest by enrollment, is one of 3 that started in 2004, is one of 6 in phase 3, and was the 1st registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 7 · Phase 4 8
First in 2002; this study’s year is marked. 3 started in 2004.
This study's enrollment of 345 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 154 across the 17 interventional studies. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 5 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
21 studies in Restless Legs Syndrome by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 21 studies in Restless Legs Syndrome by Boehringer Ingelheim, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2004, is one of 6 in phase 3, and was the 1st registered.
Boehringer Ingelheim’s Restless Legs Syndrome studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing pramipexole in Restless Legs Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 21 in Restless Legs Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A 12 week clinical trial was conducted in the United States in order to compare pramipexole (Mirapex®) versus placebo for the ability to reduce the symptoms of restless legs syndrome in adult subjects.
Change from baseline in the total score of RLSRS (Restless Legs Syndrome rating scale for severity) of the IRLSSG (International Restless Legs Syndrome Study Group)
Time frame: week 12
CGI-I (CGI-Improvement)
Time frame: week 12
RLSRS response (≥50% reduction from baseline in RLSRS)
Time frame: at week 4, 6 and 12
CGI-I responder analysis
Time frame: at week 4, 6 and 12
Change from baseline in CGI-Severity
Time frame: at week 4, 6 and 12
CGI-therapeutic effect
Time frame: at week 4, 6 and 12
CGI-Side effects
Time frame: at week 4, 6 and 12
Patient Global Impression (PGI)
Time frame: at week 1-4, 6 and 12
Visual analogue scales to assess RLS severity before sleep onset, during night and during day, and satisfaction with sleep
Time frame: at week 4, 6 and 12
Change from baseline in Epworth sleepiness scale (ESS)
Time frame: at week 4, 6 and 12
Change from baseline in RLS-QOL (Johns Hopkins Restless Legs Syndrome Quality of Life questionnaire)
Time frame: at week 6 and 12
Change from baseline in Augmentation Severity Rating Scale of IRLSSG
Time frame: at week 6 and 12
Change in systolic and diastolic blood pressure (after 5 minutes supine and subsequently after 1 minute standing)
Time frame: week 12
Change in pulse rate (palpation after 5 minute supine and subsequent after 1 minute standing)
Time frame: week 12
Change in routine laboratory tests
Time frame: week 12
Change in Physical examinations including eye examinations with ophthalmoscopic retinal eye examinations and a full skin dermatologic examination
Time frame: week 12
Change in Electrocardiogram
Time frame: 12 weeks
Incidence of Adverse evens (including withdrawal symptoms and rebound symptoms)
Time frame: up to 93 days
Concomitant medication reporting
Time frame: 12 weeks
Early withdrawal phenomena
Time frame: 12 weeks
Assessment of sudden onset of sleep (SOOS)
Time frame: up to 93 days
The record gives a start of Apr 2004, a primary completion of Feb 2005 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole